Intranasal drug delivery: Novel delivery route for effective management of neurological disorders

Patel, Ashwini; Surti, Nazneen; Mahajan, Arpana

doi:10.1016/j.jddst.2019.04.017

Cited by 13 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nose to brain delivery has been displayed in both preclinical and clinical studies with a variety of formulations, which include nasal sprays, powders, gels, and nanoemulsions [ 34 , 35 ]. The olfactory nerve pathway should be the portal of entry of NPs into the human brain via the olfactory bulbs [ [36] , [37] , [38] ].…”

Section: Nose To Brain Transport Pathways: a Concise Overviewmentioning

confidence: 99%

Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs

Mignani

Shi

Karpus

et al. 2021

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

There are several routes of administration to the brain, including intraparenchymal, intraventricular, and subarachnoid injections. The blood-brain barrier (BBB) impedes the permeation and access of most drugs to the central nervous system (CNS), and consequently, many neurological diseases remain undertreated. For past decades, to circumvent this effect, several nanocarriers have been developed to deliver drugs to the brain. Importantly, intranasal (IN) administration can allow direct delivery of drugs into the brain through the anatomical connection between the nasal cavity and brain without crossing the BBB. In this regard, dendrimers may possess great potential to deliver drugs to the brain by IN administration, bypassing the BBB and reducing systemic exposure and side effects, to treat diseases of the CNS. In this original concise review, we highlighted the few examples advocated regarding the use of dendrimers to deliver CNS drugs directly via IN. This review highlighed the few examples of the association of dendrimer encapsulating drugs ( e.g. , small compounds: haloperidol and paeonol; macromolecular compounds: dextran, insulin and calcitonin; and siRNA) using IN administration. Good efficiencies were observed. In addition, we will present the in vivo effects of PAMAM dendrimers after IN administration, globally, showing no general toxicity.

show abstract

Section: Nose To Brain Transport Pathways: a Concise Overviewmentioning

confidence: 99%

Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs

Mignani

Shi

Karpus

et al. 2021

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…The nose-to-brain delivery has been displayed in both preclinical and clinical studies with a variety of formulations such as nasal sprays, powders, gels, etc. [89].…”

Section: Bypassing the Bbb With Noninvasive Approachesmentioning

confidence: 99%

Dendrimer-Based Drug Delivery Systems for Brain Targeting

2019

View full text Add to dashboard Cite

Human neuroscience has made remarkable progress in understanding basic aspects of functional organization; it is a renowned fact that the blood–brain barrier (BBB) impedes the permeation and access of most drugs to central nervous system (CNS) and that many neurological diseases remain undertreated. Therefore, a number of nanocarriers have been designed over the past few decades to deliver drugs to the brain. Among these nanomaterials, dendrimers have procured an enormous attention from scholars because of their nanoscale uniform size, ease of multi-functionalization, and available internal cavities. As hyper-branched 3D macromolecules, dendrimers can be maneuvered to transport diverse therapeutic agents, incorporating small molecules, peptides, and genes; diminishing their cytotoxicity; and improving their efficacy. Herein, the present review will give exhaustive details of extensive researches in the field of dendrimer-based vehicles to deliver drugs through the BBB in a secure and effectual manner. It is also a souvenir in commemorating Donald A. Tomalia on his 80th birthday.

show abstract

“…Spray drug particles can enter the brain through the neuroepithelium via the nasal cavity pathway when administered intranasally. 28 By using an advanced focused ultrasonic oscillation mechanism, microbubble-mediated focused ultrasound can temporarily open the BBB, allowing drugs to enter the brain. To significantly improve the effectiveness of intranasally delivered drugs in entering the FUS-targeted areas of the brain, focused ultrasound-mediated intranasal brain drug delivery uses focused ultrasound in combination with microbubbles.…”

Section: Introductionmentioning

confidence: 99%